169 related articles for article (PubMed ID: 26196503)
1. Esters of Bendamustine Are by Far More Potent Cytotoxic Agents than the Parent Compound against Human Sarcoma and Carcinoma Cells.
Huber S; Huettner JP; Hacker K; Bernhardt G; König J; Buschauer A
PLoS One; 2015; 10(7):e0133743. PubMed ID: 26196503
[TBL] [Abstract][Full Text] [Related]
2. Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.
Arimany-Nardi C; Montraveta A; Lee-Vergés E; Puente XS; Koepsell H; Campo E; Colomer D; Pastor-Anglada M
Pharmacogenomics J; 2015 Aug; 15(4):363-71. PubMed ID: 25582574
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine-PAMAM Conjugates for Improved Apoptosis, Efficacy, and in Vivo Pharmacokinetics: A Sustainable Delivery Tactic.
Gothwal A; Khan I; Kumar P; Raza K; Kaul A; Mishra AK; Gupta U
Mol Pharm; 2018 Jun; 15(6):2084-2097. PubMed ID: 29195048
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine: role and evidence in lymphoma therapy, an overview.
Derenzini E; Zinzani PL; Cheson BD
Leuk Lymphoma; 2014 Jul; 55(7):1471-8. PubMed ID: 24180334
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance.
Heise M; Lautem A; Knapstein J; Schattenberg JM; Hoppe-Lotichius M; Foltys D; Weiler N; Zimmermann A; Schad A; Gründemann D; Otto G; Galle PR; Schuchmann M; Zimmermann T
BMC Cancer; 2012 Mar; 12():109. PubMed ID: 22439694
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of the organic cation transporters (OCTs) in human airway pulmonary epithelial cells.
Ingoglia F; Visigalli R; Rotoli BM; Barilli A; Riccardi B; Puccini P; Dall'Asta V
Biochim Biophys Acta; 2015 Jul; 1848(7):1563-72. PubMed ID: 25883089
[TBL] [Abstract][Full Text] [Related]
8. Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake.
Hagos Y; Hundertmark P; Shnitsar V; Marada VV; Wulf G; Burckhardt G
Am J Physiol Renal Physiol; 2015 Feb; 308(4):F330-8. PubMed ID: 25477469
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable nano-architectural PEGylated approach for the improved stability and anticancer efficacy of bendamustine.
Khan I; Gothwal A; Sharma AK; Qayum A; Singh SK; Gupta U
Int J Biol Macromol; 2016 Nov; 92():1242-1251. PubMed ID: 27527691
[TBL] [Abstract][Full Text] [Related]
10. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Cheson BD; Brugger W; Damaj G; Dreyling M; Kahl B; Kimby E; Ogura M; Weidmann E; Wendtner CM; Zinzani PL
Leuk Lymphoma; 2016; 57(4):766-82. PubMed ID: 26592922
[TBL] [Abstract][Full Text] [Related]
11. Impact of Organic Cation Transporters (OCT-SLC22A) on Differential Diagnosis of Intrahepatic Lesions.
Visentin M; van Rosmalen BV; Hiller C; Bieze M; Hofstetter L; Verheij J; Kullak-Ublick GA; Koepsell H; Phoa SS; Tamai I; Bennink RJ; van Gulik TM; Stieger B
Drug Metab Dispos; 2017 Feb; 45(2):166-173. PubMed ID: 27903597
[TBL] [Abstract][Full Text] [Related]
12. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
13. Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies.
Penne M; Sarraf Yazdy M; Nair KS; Cheson BD
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):637-644. PubMed ID: 28797620
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma.
Lautem A; Heise M; Gräsel A; Hoppe-Lotichius M; Weiler N; Foltys D; Knapstein J; Schattenberg JM; Schad A; Zimmermann A; Otto G; Lang H; Galle PR; Schuchmann M; Zimmermann T
Int J Oncol; 2013 Apr; 42(4):1297-304. PubMed ID: 23440379
[TBL] [Abstract][Full Text] [Related]
15. A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells.
Yu J; Qiu S; Ge Q; Wang Y; Wei H; Guo D; Chen S; Liu S; Li S; Xing H; Rao Q; Wang J; Wang M
Oncotarget; 2015 Aug; 6(24):20121-31. PubMed ID: 26015396
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of STAT3 by Anticancer Drug Bendamustine.
Iwamoto K; Uehara Y; Inoue Y; Taguchi K; Muraoka D; Ogo N; Matsuno K; Asai A
PLoS One; 2017; 12(1):e0170709. PubMed ID: 28125678
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine: mechanism of action and clinical data.
Cheson BD; Leoni L
Clin Adv Hematol Oncol; 2011 Aug; 9(8 Suppl 19):1-11. PubMed ID: 22362008
[TBL] [Abstract][Full Text] [Related]
19. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine reactivates latent Epstein-Barr virus.
Fernandez SG; Miranda JJ
Leuk Lymphoma; 2016 May; 57(5):1208-10. PubMed ID: 26371746
[No Abstract] [Full Text] [Related]
[Next] [New Search]
